Company: APXIF
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026339
Chunk: 135

Company: APx Acquisition Corp. I
Filing Date: 2025-03-31
Form: F-4/A
Chunk 135
---
 associated with payment collection generally. Any inability to maintain our past payment collection levels could cause our revenue and ability to achieve profitability to decline and adversely affect our business, prospects and financial condition. The uncertainty of receiving payment for our tests and complex laboratory billing processes could negatively affect our business, financial condition, results of operations and growth prospects. We may incur significant losses from fraud. We may in the future incur losses from various types of fraud, including stolen credit card numbers, claims that a customer did not authorize a purchase and customers who have closed bank accounts or have insufficient bank accounts to satisfy payments. We provide our Rewell genetic tests as direct -to -customerto the general population, currently constituting 5% of our total revenue. In Argentina, we accept payment via bank transfer, credit card payments, and cryptocurrency. Although we have measures in place to detect and reduce the occurrence of fraudulent activity on our platforms, those measures may not always be effective. In addition to the direct costs of such losses, if the fraud is related to credit card transactions and becomes excessive, it could potentially result in us paying higher fees or losing the right to accept credit cards for payment. In addition, under current credit card practices, we are liable for fraudulent credit card transactions because we do not obtain a cardholder’s signature for online purchases on our platform. Our failure to adequately prevent fraudulent transactions could damage our reputation, result in litigation or regulatory action and additional expenses which all could negatively affect our business, financial condition, results of operations and growth prospects. Our pricing strategies may not meet customers’ price expectations or may adversely affect our revenues. Our pricing strategies have had and may continue to have a significant impact on our revenue. Periodically, we offer discounted prices and promotions for our Rewell offering to attract customers, including strategic partners. However, such offers and discounts may reduce our revenue and margins. Additionally, if our competitors engage in aggressive pricing strategies or other competitive activities, or if our own pricing strategies, which may evolve over time, fail to meet the price expectations of our customers and strategic partners or fail to increase margins, it could materially and adversely affect our business, financial condition, results of operations, and growth prospects. If we are unable to attract and retain high quality healthcare providers for our patients, our business, financial condition, and results of operations may be materially and adversely affected. Our success is dependent upon our continued ability to maintain a network of qualified telehealth providers. If we are unable to recruit and retain scientists, board -certifiedphysicians, and other